Smart Insulin Pumps Improve Blood Sugar in Toddlers with Type 1 Diabetes

What Was Studied — and Why It Matters

Managing type 1 diabetes in toddlers and preschoolers is one of the hardest challenges in pediatric medicine. Young children can't communicate symptoms clearly, their insulin needs change rapidly, and poor blood sugar control during these early years can affect brain development. Researchers wanted to know: could an automated insulin delivery (AID) system — essentially a "smart" insulin pump — do a better job than traditional pump management in children aged 2 to 6?

The LENNY trial, published in The Lancet Diabetes & Endocrinology, set out to answer that question with rigorous clinical evidence across 98 children in Finland, Italy, Slovenia, and the UK.

How the Study Worked

Children were placed on the MiniMed 780G system — a pump that continuously monitors glucose and automatically adjusts insulin delivery — and tested in two different modes:

• Auto Mode: The pump controlled insulin delivery automatically based on real-time glucose readings
• Manual Mode (with Low Suspend): Parents managed settings manually, with the pump only stepping in to pause insulin if levels dropped dangerously low

Each child spent 12 weeks in each mode, and researchers measured two key outcomes: Time in Range (TIR) — the percentage of hours blood sugar stayed between 70–180 mg/dL — and HbA1c, a 3-month average of blood sugar levels.

What the Findings Show

The results strongly favored the automated system:

• Children in Auto Mode spent 68% of the time in healthy blood sugar range, compared to just 58% in manual mode — a meaningful 10-percentage-point improvement
• Average HbA1c dropped to 7.0% in Auto Mode versus 7.6% in manual mode — a clinically significant difference that reduces long-term complication risk
• No severe low blood sugar (hypoglycemia) events were recorded during the entire trial
• Serious side effects were rare and not linked to the device itself

What This Means for Families

For parents of very young children with type 1 diabetes, this research is genuinely encouraging. It shows that automated technology can safely take on much of the around-the-clock guesswork that exhausts caregivers — especially overnight. Better blood sugar stability during these critical developmental years may also protect long-term brain health.

If your child uses a continuous glucose monitor (CGM) or insulin pump, keeping reliable supplies on hand is essential to making these systems work every day. MDS Diabetes offers a wide range of diabetes management supplies to help families stay consistently equipped without interruption.

Important Caveats

This trial used one specific system (MiniMed 780G), so results may vary with other AID devices. The study also ran for about 6 months — longer-term data is still needed. Families should always work closely with their child's endocrinologist before changing any treatment approach.

Bottom Line

Automated insulin delivery systems significantly outperformed manual pump management in children aged 2–6 with type 1 diabetes, boosting healthy blood sugar time by 10 percentage points and lowering HbA1c — all without raising safety concerns. For caregivers navigating the enormous challenge of toddler diabetes management, this technology represents a meaningful, evidence-backed step forward.